Jeffrey Hessekiel - 14 Nov 2025 Form 4 Insider Report for CYTOKINETICS INC (CYTK)

Role: Chief Legal & Admin Officer
Signature: /s/ John O. Faurescu, attorney-in-fact for Mr. Hessekiel
Issuer symbol: CYTK
Transactions as of: 14 Nov 2025
Net transactions value: $0
Form type: 4
Filing time: 17 Nov 2025, 16:02:48 UTC
Previous filing: 14 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hessekiel Jeffrey	Chief Legal & Admin Officer	350 OYSTER POINT BLVD, SOUTH SAN FRANCISCO	/s/ John O. Faurescu, attorney-in-fact for Mr. Hessekiel	17 Nov 2025	0001599803

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYTK	Common Stock	Award	$0	+87,297		$0.000000	87,297	14 Nov 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Initial new hire grant comprised of restricted stock units ("RSUs") that are convertible to shares of common stock on a 1:1 basis upon vesting. RSUs will vest as follows: 40% of the aggregate RSUs on the date falling 1-year from the date of grant, an additional 40% of the aggregate RSUs on the date falling 2-years from the date of grant, and the remaining 20% of the aggregate RSUs on the date falling 3-years from the date of grant, in each case subject to Mr. Hessekiel's continued employment with Cytokinetics.

Content

Initial new hire grant comprised of restricted stock units ("RSUs") that are convertible to shares of common stock on a 1:1 basis upon vesting. RSUs will vest as follows: 40% of the aggregate RSUs on the date falling 1-year from the date of grant, an additional 40% of the aggregate RSUs on the date falling 2-years from the date of grant, and the remaining 20% of the aggregate RSUs on the date falling 3-years from the date of grant, in each case subject to Mr. Hessekiel's continued employment with Cytokinetics.